Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer.

Autor: Parekh J; Yale New Haven Health System, Bridgeport Hospital, Bridgeport, CT, USA., Parikh K; Mayo Clinic, Rochester, MN, USA., Reuss JE; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA., Friedlaender A; Clinique General Beaulieu, Geneva, Switzerland.; University Hospital Geneva, Geneva, Switzerland., Addeo A; University Hospital Geneva, Geneva, Switzerland. alfredo.addeo@hcuge.ch.
Jazyk: angličtina
Zdroj: Current oncology reports [Curr Oncol Rep] 2023 Aug; Vol. 25 (8), pp. 913-922. Date of Electronic Publication: 2023 May 30.
DOI: 10.1007/s11912-023-01430-4
Abstrakt: Purpose of Review: For decades, early-stage resectable non-small cell lung cancer (NSCLC), while potentially curable, has been marred by unacceptably high recurrence rates.
Recent Findings: Anti-PD(L)1 immune checkpoint blockade (ICB) has revolutionized the treatment of advanced NSCLC, and with recent approvals in the peri-operative space, is now poised to transform the systemic treatment paradigm for localized and locally-advanced NSCLC. In this review, we focus on neoadjuvant ICB in resectable NSCLC, highlighting the pre-clinical rationale for neoadjuvant ICB, early clinical trials, randomized phase 3 trial data, and future directions for resectable NSCLC.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: